Elubous Khaled Ali, Alebous Ali D, Abous Hebah A, Elubous Rawan A
Department of Ophthalmology, University of Jordan, Amman, Jordan.
Department of Surgery, King Hussein Cancer Center, Amman, Jordan.
SN Compr Clin Med. 2021;3(12):2593-2602. doi: 10.1007/s42399-021-01068-y. Epub 2021 Sep 22.
Evaluation of the research trends in uveal melanoma in the past two decades. Data were extracted from the Web of Science database website. VOSviewer and Citespace software were used to analyze the retrieved data. The leading country in terms of output and international collaboration is the USA. Research interest in genetic mutations, molecular pathways, and immunotherapy was remarkable in recent years. Most of the top ten journals are specialized in ophthalmology. In recent years, the hotspots include future perspectives, mutation, therapeutic target, and systematic reviews. The keywords with the strongest citation bursts are immunotherapy, outcome, and in situ hybridization. The output of uveal melanoma research increased during the past two decades. Before 2015, the main focus of the research was to facilitate prognostication and metastatic risk stratification. Recently, research has moved to examine the metastatic microenvironment. Future research foci may include exploring the role of different mutations, immunotherapy, molecular alterations, and finding ideal clinical biomarkers.
过去二十年葡萄膜黑色素瘤研究趋势评估。数据从科学网数据库网站提取。使用VOSviewer和Citespace软件分析检索到的数据。在产出和国际合作方面领先的国家是美国。近年来,对基因突变、分子途径和免疫疗法的研究兴趣显著。前十的期刊大多专门研究眼科。近年来,热点包括未来展望、突变、治疗靶点和系统评价。引用爆发最强的关键词是免疫疗法、结果和原位杂交。过去二十年葡萄膜黑色素瘤研究的产出有所增加。2015年之前,研究的主要重点是促进预后和转移风险分层。最近,研究已转向研究转移微环境。未来的研究重点可能包括探索不同突变、免疫疗法、分子改变的作用以及寻找理想的临床生物标志物。
SN Compr Clin Med. 2021
Int Ophthalmol. 2022-4
Front Med (Lausanne). 2022-1-3
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2019-12-30
Turk J Ophthalmol. 2024-10-25
Br J Cancer. 2021-4
PeerJ. 2019-10-30
BMC Complement Altern Med. 2019-8-22
Cancers (Basel). 2019-8-17
Cancers (Basel). 2019-6-18
Cancer Immunol Immunother. 2019-6-7
Cancer Chemother Pharmacol. 2019-5-11
Int Immunopharmacol. 2019-4-24
Mol Cancer. 2019-3-30